To understand the importance of different subsets of CD14+CD169+ macrophages in the development of CRC, the percentages of different subsets of CD14+CD169+ macrophages in LPMCs from 12 non-tumor patients and in TIMs from 30 CRC patients were analyzed by flow cytometry (Fig 2A). The gene discussed is SIGLEC1; the disease is colorectal carcinoma.